Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filapixant (BAY1902607) in Healthy Males and Refractory Chronic Cough
NCT03535168Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of filapixant in refractory chronic cough (RCC), sponsored by Bayer. Started May 2018; status: completed.
02
Drugs
filapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT03535168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535168.